Orexin-A, also known as hypocretin-1, is a hypothalamic neuropeptide that promotes wakefulness, arousal and appetite regulation, and is investigated exclusively in preclinical mechanistic animal research for those mechanisms. Clinician reports describe a typical regimen of 1 mg administered intranasal each day, with no specified timing or cycling schedule, based on a single Peptide List source. No community‑derived use patterns have been recorded overall to date, and because the peptide lacks FDA‑approval, any human use remains off‑label or relies on compounded preparations.
Data last updated
Measured on 2 of 6 axes
Evidence shape
Orexin-A currently has only animal‑only evidence, limited to preclinical or mechanistic research, with zero human‑published studies reported and no human indications populated or thin indications recorded. The breadth of data consists of a single animal‑only indication mapped, while the depth shows zero registered trials, no completed human trials, and no posted results. Consequently, the absence of any human trial data signals that the peptide remains unexplored in clinical settings, with only preclinical work available.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Symptom-relevant clinical or community evidence has not been captured for this peptide yet.
price offers can be sorted by column
How Orexin-A is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
In clinician reports, Orexin‑A is administered intranasally at a fixed dose of 1 mg each day, with the dose range also reported as 1 mg to 1 mg; no cycling schedule is described in the available data.
No structured protocol details captured for this tier yet.